COPENHAGEN (Reuters) - Danish drugmaker Novo Nordisk, the world's biggest insulin maker, said on Friday it had received positive results from a phase 2 trial of an oral version of a long-acting GLP-1 for treatment of people with type 2 diabetes.
via Reuters: Health News Read More Here..
No comments:
Post a Comment